JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Utility of serum chemokine-like factor 1 as a biomarker of severity and prognosis after severe traumatic brain injury: A prospective observational study

  • 0Department of Neurosurgery, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Brain and Behavior +

|

May 22, 2024

|

May 22, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Elevated serum Chemokine-like factor 1 (CKLF1) levels in severe traumatic brain injury (sTBI) patients correlate with disease severity and predict poor outcomes. CKLF1 shows potential as a prognostic biomarker for sTBI patients.

Area Of Science

  • Neuroscience
  • Immunology
  • Biomarker Discovery

Background

  • Severe traumatic brain injury (sTBI) involves complex inflammatory responses and secondary injury.
  • Chemokine-like factor 1 (CKLF1) is implicated in inflammatory processes.
  • The prognostic role of CKLF1 in sTBI requires further investigation.

Purpose Of The Study

  • To determine serum CKLF1 levels in sTBI patients.
  • To investigate the correlation between CKLF1 levels and sTBI disease severity.
  • To assess the association of CKLF1 with functional prognosis and 180-day mortality in sTBI.

Main Methods

  • Serum CKLF1 levels measured in 119 sTBI patients and 119 controls.
  • Serial CKLF1 measurements performed on sTBI patients up to 7 days post-injury.
  • Disease severity assessed using Glasgow Coma Scale (GCS) and Rotterdam CT classification.
  • Functional prognosis evaluated with Extended Glasgow Outcome Scale (GOSE) at 180 days.
  • Statistical analyses included univariate, multivariate, and ROC curve analyses.

Main Results

  • Serum CKLF1 levels were significantly elevated in sTBI patients compared to controls, peaking on day 2.
  • Higher CKLF1 levels correlated independently with lower GCS scores, severe Rotterdam CT classification, and poorer GOSE scores.
  • Elevated CKLF1 levels were associated with increased 180-day mortality and poor prognosis.
  • CKLF1 demonstrated significant predictive ability for prognosis and mortality, comparable to GCS and CT classification.
  • A combined model of CKLF1, GCS, and CT classification improved predictive efficiency for mortality and poor prognosis.

Conclusions

  • Serum CKLF1 levels are significantly associated with sTBI severity and 180-day outcomes.
  • CKLF1 serves as a potential independent prognostic biomarker for sTBI.
  • Combining CKLF1 with established clinical and radiological markers enhances prognostic accuracy.

Keywords: